CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that Director and…
Read More
$5 million upfront with up to approximately $8.9 million of potential aggregate proceeds upon the exercise in full of warrants CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or…
Read More
$5 million upfront with up to approximately $8.9 million of potential aggregate proceeds upon the exercise in full of warrants CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or…
Read More
Patent provides added depth to Enveric's EVM301 intellectual property portfolio of potential neuroplastogenic molecules for non-hallucinogenic treatment of neuropsychiatric conditions CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the…
Read More
Product Development Highlights: Reported positive preclinical results for lead drug candidate EB-003, showing statistically significant improvements in animal models of severe chronic depression and despair and in post-traumatic stress disorder…
Read More
Canadian Trademark Office Issues House Marks to Enveric Biosciences, Inc. CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to…
Read More
As a result of this action, there are no remaining challenges currently pending against Enveric's patent CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company…
Read More
Proprietary assays demonstrate dual Gq and β-arrestin signaling at 5-HT A, pathways linked in peer-reviewed studies to antidepressant and anxiolytic effects A recent independent Nature study reports that distinct signaling…
Read More
RCANN™ Trademark Portfolio Out-Licensed CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders,…
Read More
CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing…
Read More
